Related references
Note: Only part of the references are listed.Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model
Joy C. Yang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer
Joy C. Yang et al.
CANCER RESEARCH (2009)
STAT3 inhibits the degradation of HIF-1α by pVHL-mediated ubiquitination
Joo Eun Jung et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2008)
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530
Y-M Chang et al.
ONCOGENE (2008)
Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer
Cheryl A. Grandinetti et al.
PHARMACOTHERAPY (2007)
Renal cancer cells lacking hypoxia inducible factor (HIF)-1 alpha expression maintain vascular endothelial growth factor expression through HIF-2 alpha
Toshiaki Shinojima et al.
CARCINOGENESIS (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor
Laurent F. Hennequin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Systems biology and combination therapy in the quest for clinical efficacy
Jonathan B. Fitzgerald et al.
NATURE CHEMICAL BIOLOGY (2006)
Clinical development of Src tyrosine kinase inhibitors in lung cancer
David Lee et al.
CLINICAL LUNG CANCER (2006)
Treatment for advanced tumors: Src reclaims center stage
JM Summy et al.
CLINICAL CANCER RESEARCH (2006)
Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells
Y Yonezawa et al.
MOLECULAR CARCINOGENESIS (2005)
HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complexthat regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas
MJ Gray et al.
ONCOGENE (2005)
Novel treatments for metastatic renal cell carcinoma
DJ van Spronsen et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Hypoxia-inducible factor-1 and oncogenic signalling
JI Bárdos et al.
BIOESSAYS (2004)
c-Src and cooperating partners in human cancer
R Ishizawar et al.
CANCER CELL (2004)
Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials
A Sistla et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2004)
Share Paper
